Top Markets
#1 Seeker Seeker +45.46%
#2 Helium Helium +36.27%
#3 TENDIES TENDIES +29.33%
#4 Pons Pons +28.89%
#5 pipedog pipedog +20.31%
#6 UnifAI Network UnifAI Network +19.15%
#7 Zylo Ecosystem Zylo Ecosystem +19.08%
#8 Bounce Bounce +18.99%
#9 ZKsync ZKsync +14.63%
#10 Zora Zora +14.14%
Coin of the day
Seeker Seeker
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Rang in Aktien #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Aktienkurs
$9.50
Zuletzt synchronisiert: 2025-01-08
Marktkapitalisierung
$819.52M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Poseida Therapeutics, Inc. (PSTX)

Kategorie

Healthcare
Anzahl der ausstehenden Aktien von Poseida Therapeutics, Inc. (PSTX)
Anzahl der ausstehenden Aktien zum September 2024: 97.16M
Laut den neuesten Finanzberichten und dem Aktienkurs von Poseida Therapeutics, Inc. beträgt die aktuelle Anzahl der ausstehenden Aktien 97.16M. Am Ende von December 2022 hatte das Unternehmen 71.91M ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von Poseida Therapeutics, Inc. (PSTX) von 2016 bis 2026
Ausstehende Aktien am Ende jedes Jahres
Jahr Ausstehende Aktien ändert
2026 (TTM) 97.16M 7.73%
2023 90.19M 25.41%
2022 71.91M 15.66%
2021 62.18M 6.47%
2020 58.40M 46.98%
2019 39.73M 10.59%
2018 35.93M -9.57%
2017 39.73M -33.01%
2016 59.32M 0.00%
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
Unternehmen Ausstehende Aktien Unterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 161.32%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -36.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 392.91%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 307.57%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH